









OVERVIEW BY GEOGRAPHIC SEGMENT

JAPAN	EUROPE
<p>RATIO OF SALES BY REGION</p>  <p>NET SALES ¥162.1 Billion OPERATING INCOME ¥51.4 Billion</p> <p>CONSOLIDATED NET SALES (Billion ¥)</p>  <p>Infusion sets and blood transfusion products saw steady growth in sales. Sales of pharmaceuticals and cardiac and vascular products, however, declined. This was due to downward revisions in pharmaceutical prices and official reimbursement prices under the National Health Insurance, as well as factors such as the voluntary recall of “Hepaflush” prefilled syringes as a preventative measure.</p> <p>As a result, sales declined 0.2% year on year to ¥162.1 billion, and operating income amounted to ¥51.4 billion.</p>	<p>RATIO OF SALES BY REGION</p>  <p>NET SALES ¥55.7 Billion OPERATING INCOME ¥7.0 Billion</p> <p>CONSOLIDATED NET SALES (Billion ¥)</p>  <p>Overall sales of interventional systems rose, led by the new drug-eluting stent, which was aggressively promoted. Blood transfusion products also grew. Double-digit growth was recorded on a local-currency basis. However, currency exchange rates exercised a major downward impact.</p> <p>As a result, sales declined 1.9% year on year to ¥55.7 billion, and operating income amounted to ¥7.0 billion.</p>
<p>AMERICAS</p> <p>RATIO OF SALES BY REGION</p>  <p>NET SALES ¥56.5 Billion OPERATING INCOME ¥2.5 Billion</p> <p>CONSOLIDATED NET SALES (Billion ¥)</p>  <p>Micro Vention, Inc.'s devices for treating cerebral aneurysm drove sales, while overall interventional system sales also rose. Double-digit growth was recorded on a local-currency basis, however sales on a yen-basis declined, due to the effects of currency exchange rates.</p> <p>As a result, sales declined 3.8% year on year to ¥56.5 billion, and operating income amounted to ¥2.5 billion.</p>	<p>ASIA AND OTHERS</p> <p>RATIO OF SALES BY REGION</p>  <p>NET SALES ¥28.4 Billion OPERATING INCOME ¥7.4 Billion</p> <p>CONSOLIDATED NET SALES (Billion ¥)</p>  <p>Sales of interventional systems grew strongly in China and all other countries, recording double-digit growth on a local-currency basis. However, sales were greatly impacted by such factors as the significant across-the-board drop in the value of local currencies against the major currencies as a result of the financial and economic crisis.</p> <p>As a result, sales rose 0.3% year on year to ¥28.4 billion, and operating income amounted to ¥7.4 billion.</p>

Note: Here, and on the following pages, operating income by geographic segment excludes elimination or corporate expenses.